Journal of Neuroimmune Pharmacology

, Volume 2, Issue 1, pp 93–96

Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS

  • Stephen Dewhurst
  • Sanjay B. Maggirwar
  • Giovanni Schifitto
  • Howard E. Gendelman
  • Harris A. Gelbard
Invited Review

DOI: 10.1007/s11481-006-9051-1

Cite this article as:
Dewhurst, S., Maggirwar, S.B., Schifitto, G. et al. Jrnl Neuroimmune Pharm (2007) 2: 93. doi:10.1007/s11481-006-9051-1
  • 161 Views

Abstract

Highly active antiretroviral therapy (HAART) has made a significant impact on the lives of people living with HIV-1 infection. The incidence of neurologic disease associated with HIV-1 infection of the CNS plummeted between 1996–2000, but unfortunately the number of people currently HIV-1 infected (i.e., prevalence) with associated cognitive impairment has been steadily rising. While the reasons for this may be multifactorial, the implication is clear: there is a pressing need for adjunctive therapy directed at reversing or preventing damage to vulnerable pathways in the central nervous system (CNS) from HIV-1 infection. Using a team of preclinical and clinical investigators, we have focused our efforts on defining how proinflammatory mediators and secretory neurotoxins from HIV-1 disrupt signaling of the survival-regulating enzyme, glycogen synthase kinase 3 beta (GSK-3β). In a series of studies initiated using in vitro, then in vivo models of HIV-1-associated dementia (HAD), we have demonstrated the ability of the mood stabilizing and anticonvulsant drug, sodium valproate (VPA), that inhibits GSK-3β activity and other downstream mediators, to reverse HIV-1-induced damage to synaptic pathways in the CNS. Based on these results, we successfully performed pharmacokinetic and safety and tolerability trials with VPA in a cohort of HIV-1-infected patients with neurologic disease. VPA was well tolerated in this population and secondary measures of brain metabolism, as evidenced by an increase in N-acetyl aspartate/creatine (NAA/Cr), further suggested that VPA may improve gray matter integrity in brain regions damaged by HIV-1. These findings highlight the therapeutic potential of GSK-3β blockade.

Keywords

glycogen synthase kinase 3 betahistone deacetylase type 3human immunodeficiency virus type 1HIV-1 associated dementianeuroprotection

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Stephen Dewhurst
    • 3
  • Sanjay B. Maggirwar
    • 3
  • Giovanni Schifitto
    • 2
  • Howard E. Gendelman
    • 5
    • 6
  • Harris A. Gelbard
    • 1
    • 2
    • 3
    • 4
    • 7
  1. 1.Center for Aging and Developmental BiologyUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Department of NeurologyUniversity of Rochester Medical CenterRochesterUSA
  3. 3.Department of Microbiology and ImmunologyUniversity of Rochester Medical CenterRochesterUSA
  4. 4.Department of PediatricsUniversity of Rochester Medical CenterRochesterUSA
  5. 5.Center for Neurovirology and Neurodegenerative DisordersUniversity of Nebraska Medical CenterOmahaUSA
  6. 6.Department of Pharmacology and Experimental NeuroscienceUniversity of Nebraska Medical CenterOmahaUSA
  7. 7.Center for Aging and Developmental BiologyRochesterUSA